Japan Postoperative Nausea & Vomiting (PONV) Treatment Market Insight
The Japan Postoperative Nausea & Vomiting (PONV) Treatment market is growing at a 6.61% CAGR, driven by increasing surgical procedures, rising awareness regarding post-surgical recovery management, and growing adoption of advanced antiemetic therapies. PONV remains one of the most common complications after anesthesia and surgery, increasing demand for effective serotonin antagonists, neurokinin-1 inhibitors, and combination therapies across hospitals and surgical centers.
Japan Postoperative Nausea & Vomiting (PONV) Treatment Market Insights Forecasts to 2035
- The Japan Postoperative Nausea & Vomiting (PONV) Treatment Market Size Was Estimated at USD 260.9 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.61% from 2025 to 2035
- The Japan Postoperative Nausea & Vomiting (PONV) Treatment Market Size is Expected to Reach USD 494.8 Million by 2035
Notable Insights for Japan Postoperative Nausea & Vomiting (PONV) Treatment Market
- By drug class, the 5-HT3 receptor antagonists segment dominated the market, accounting for over 45%–50% share, driven by widespread clinical use of ondansetron and related antiemetic drugs in perioperative care
- By treatment type, the combination therapy segment is expected to witness the fastest growth, supported by increasing adoption of multimodal antiemetic protocols, with growth projected at over 7%–8% CAGR
- Approximately 70%–75% of demand is driven by hospitals and surgical centers, where PONV prevention is integrated into enhanced recovery after surgery (ERAS) protocols. Additionally, hospitals accounted for 53.7% share of the global PONV treatment market in 2024
Download the eBook (ToC)
- Government healthcare initiatives and increasing surgical procedures are strengthening the Japan PONV Treatment Market, as Japan represented 32.9% of the Asia-Pacific PONV treatment market in 2024, supported by advanced healthcare infrastructure and aging population trends
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Postoperative Nausea & Vomiting (PONV) Treatment market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Postoperative Nausea & Vomiting (PONV) Treatment Market
- Pfizer Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Roche Holding AG
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Eisai Co., Ltd.
- Novartis AG
- Others
Recent Developments:
- In March 2026, pharmaceutical companies expanded development of next-generation antiemetic therapies and combination treatment regimens to improve postoperative recovery outcomes and reduce hospital stay duration
- In October 2025, hospitals in Japan increasingly adopted ERAS (Enhanced Recovery After Surgery) protocols integrating multimodal PONV prevention strategies, improving patient satisfaction and reducing postoperative complications
Market Segmentation:
Japan Postoperative Nausea & Vomiting (PONV) Treatment Market, By Drug Class
- 5-HT3 Receptor Antagonists
- NK-1 Receptor Antagonists
- Dopamine Antagonists
- Corticosteroids
- Others
Japan Postoperative Nausea & Vomiting (PONV) Treatment Market, By Treatment Type
- Monotherapy
- Combination Therapy
Japan Postoperative Nausea & Vomiting (PONV) Treatment Market, By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
Expert Views:
The Japan Postoperative Nausea & Vomiting (PONV) Treatment Market is poised for steady growth, driven by rising surgical procedures and increasing emphasis on patient-centric recovery care. Experts highlight that 5-HT3 receptor antagonists will dominate due to widespread clinical adoption, while combination therapies and multimodal antiemetic approaches will witness the fastest growth, ensuring improved postoperative outcomes and reduced hospitalization burden.